FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W129728305> ?p ?o ?g. }

• W129728305 endingPage "964" @default.
• W129728305 startingPage "954" @default.
• W129728305 abstract "The pharmacogenetic strategy uses the genetic association approach with the aim of identifying genes that influence clinical response to drug treatment. Association studies have focused mainly on neuroleptics (in particular clozapine) and variants in candidate genes of dopamine and serotonin systems in schizophrenic patients. Concerning the serotonin 5-HT(2A) receptor gene, the frequency of allele tyrosine (versus histidine) at 452 was greater among nonresponders, and homozygosity for the cytosine allele at 102 was more frequent among nonresponders. In the serotonin 5-HT(2C) receptor gene, a cysteine to serine substitution at 23 was considered as a predictor of good response to clozapine. Concerning the dopamine D2 receptor gene, the patients with one or two A1 alleles showed greater improvement than those with no A1 allele (Taq1A genotype). In addition, compared with patients who exhibited a Del allele at 141, patients with no Del allele showed better clinical response. Regarding the dopamine D3 receptor gene, the homozygous genotype serine/serine at 9 was found to be more frequent among the nonresponders. Finally, there was a possible relationship between the 48 bp variant number tandem repeat polymorphism in dopamine D4 receptor gene and response to neuroleptics.However, some results conflict with other data in the literature. The frequent difficulties in replication of pharmacogenetic findings can be explained by, among others: (i) the lack of a consistent definition of drug response; (ii) the use of different scales to evaluate response to treatment and the use of several cut-offs for the same scale; (iii) the sample heterogeneity and the small sample size; and (iv) the multigenic interactions. In order for research to progress, methodological consistency must be achieved, not only to form the basis of comparison among studies and to confirm or invalidate previous results, but also to allow for meta-analysis between the various studies. Nevertheless Kane et al. [Arch Gen Psychiatry 45 (1988) 789-796] have defined precise criteria of clinical response, but they are restrictive and quite difficult to set up in practice. Pharmacogenetic research has the following advantages: (i) it is based on the individual patient's genotype, invariable data in normal conditions, and can therefore be measured at any time during treatment; (ii) it uses reliable molecular biological techniques; and (iii) it is in constant progress because of the increasing amount of genomic information available.In future, a combination of several polymorphisms showing a strong association with a specific neuroleptic response could constitute a clinical test to predict the individual response to such treatment, and therefore participate in the prescription process. A research team has already proposed a combination of six polymorphisms implicating 5-HT(2A) receptor, 5-HT(2C) receptor, 5-HTTLPR, and H2 receptor genes [Lancet 355 (2000) 1615-1616], but this result has to be replicated. Until now, pharmacogenetics has focused on the global clinical response, but in the years to come, it could focus on the genes implied in the effects of treatments on specific symptoms and on physiological mechanisms that would explain how gene polymorphism can influence therapeutic response. This review aims to summarise recent advances and to present future clinical applications for pharmacogenetics." @default.
• W129728305 created "2016-06-24" @default.
• W129728305 creator A5075595871 @default.
• W129728305 creator A5091106159 @default.
• W129728305 date "2007-12-01" @default.
• W129728305 modified "2023-09-23" @default.
• W129728305 title "Approche pharmacogénétique de la réponse aux antipsychotiques chez les schizophrènes" @default.
• W129728305 cites W166467851 @default.
• W129728305 cites W1688754235 @default.
• W129728305 cites W185627204 @default.
• W129728305 cites W1963856882 @default.
• W129728305 cites W1966745635 @default.
• W129728305 cites W1972470540 @default.
• W129728305 cites W1974702488 @default.
• W129728305 cites W1975997144 @default.
• W129728305 cites W1977198272 @default.
• W129728305 cites W1978102521 @default.
• W129728305 cites W1979074282 @default.
• W129728305 cites W1979825096 @default.
• W129728305 cites W1984296918 @default.
• W129728305 cites W1985888586 @default.
• W129728305 cites W1986790792 @default.
• W129728305 cites W1994665734 @default.
• W129728305 cites W1998452434 @default.
• W129728305 cites W1999265734 @default.
• W129728305 cites W2001657113 @default.
• W129728305 cites W2005530745 @default.
• W129728305 cites W2011264636 @default.
• W129728305 cites W2015302305 @default.
• W129728305 cites W2016806846 @default.
• W129728305 cites W2019628591 @default.
• W129728305 cites W2020844317 @default.
• W129728305 cites W2024683021 @default.
• W129728305 cites W2026127806 @default.
• W129728305 cites W2026395566 @default.
• W129728305 cites W2033916831 @default.
• W129728305 cites W2041166229 @default.
• W129728305 cites W2041440098 @default.
• W129728305 cites W2045836489 @default.
• W129728305 cites W2053508950 @default.
• W129728305 cites W2055772637 @default.
• W129728305 cites W2058783998 @default.
• W129728305 cites W2059230444 @default.
• W129728305 cites W2063107423 @default.
• W129728305 cites W2069787463 @default.
• W129728305 cites W2074887429 @default.
• W129728305 cites W2077603742 @default.
• W129728305 cites W2078671723 @default.
• W129728305 cites W2079712833 @default.
• W129728305 cites W2080032492 @default.
• W129728305 cites W2080322719 @default.
• W129728305 cites W2080657207 @default.
• W129728305 cites W2081905164 @default.
• W129728305 cites W2082312328 @default.
• W129728305 cites W2085360366 @default.
• W129728305 cites W2094683019 @default.
• W129728305 cites W2102098190 @default.
• W129728305 cites W2119226169 @default.
• W129728305 cites W2128273381 @default.
• W129728305 cites W2159011576 @default.
• W129728305 cites W2159280173 @default.
• W129728305 cites W2169919448 @default.
• W129728305 cites W2314344069 @default.
• W129728305 cites W2320622591 @default.
• W129728305 cites W2412643222 @default.
• W129728305 cites W75263880 @default.
• W129728305 cites W941598985 @default.
• W129728305 doi "https://doi.org/10.1016/j.encep.2007.01.004" @default.
• W129728305 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18789788" @default.
• W129728305 hasPublicationYear "2007" @default.
• W129728305 type Work @default.
• W129728305 sameAs 129728305 @default.
• W129728305 citedByCount "1" @default.
• W129728305 countsByYear W1297283052016 @default.
• W129728305 crossrefType "journal-article" @default.
• W129728305 hasAuthorship W129728305A5075595871 @default.
• W129728305 hasAuthorship W129728305A5091106159 @default.
• W129728305 hasConcept C138885662 @default.
• W129728305 hasConcept C15708023 @default.
• W129728305 hasConceptScore W129728305C138885662 @default.
• W129728305 hasConceptScore W129728305C15708023 @default.
• W129728305 hasIssue "6" @default.
• W129728305 hasLocation W1297283051 @default.
• W129728305 hasLocation W1297283052 @default.
• W129728305 hasOpenAccess W129728305 @default.
• W129728305 hasPrimaryLocation W1297283051 @default.
• W129728305 hasRelatedWork W1777746615 @default.
• W129728305 hasRelatedWork W1977009168 @default.
• W129728305 hasRelatedWork W1992647879 @default.
• W129728305 hasRelatedWork W2006162791 @default.
• W129728305 hasRelatedWork W2033275179 @default.
• W129728305 hasRelatedWork W2038619529 @default.
• W129728305 hasRelatedWork W2056767759 @default.
• W129728305 hasRelatedWork W2080032492 @default.
• W129728305 hasRelatedWork W2753967614 @default.
• W129728305 hasRelatedWork W3032655599 @default.
• W129728305 hasVolume "33" @default.
• W129728305 isParatext "false" @default.

• next